Welcome to our dedicated page for Indaptus Therapeutics news (Ticker: INDP), a resource for investors and traders seeking the latest updates and insights on Indaptus Therapeutics stock.
Indaptus Therapeutics, Inc. (Nasdaq: INDP) is a clinical-stage biotechnology company whose news flow centers on the development of its Decoy bacterial immunotherapy platform for cancer and viral infections. The company’s updates frequently highlight progress in its clinical program for Decoy20, its lead candidate, as well as financing transactions and corporate developments disclosed through press releases and SEC filings.
Investors following INDP news can expect detailed reports on the INDP-D101 clinical trial, including the monotherapy evaluation of Decoy20 and the combination arm with the PD-1 checkpoint inhibitor tislelizumab in advanced solid tumors. Recent announcements have described safety lead-in results, individual patient responses such as a partial response in a urothelial cancer patient, and instances of stable disease in combination cohorts, along with commentary from company leadership on trial strategy and next steps.
Indaptus also issues news about scientific presentations and conference participation, where its team discusses how the Decoy platform activates innate and adaptive immune cells and its potential to support allogeneic cell therapies by enhancing donor cell potency. In addition, the company regularly reports quarterly financial results, outlining research and development spending on its Phase 1/1b/2 program, general and administrative expenses, cash runway expectations, and the impact of financings such as private placements of convertible notes, equity offerings and preferred stock transactions.
For market participants, the INDP news stream offers insight into clinical milestones, safety and early efficacy signals, intellectual property developments, capital structure changes, reverse stock split implementation, and board and management updates. Monitoring this page provides a consolidated view of how Indaptus is advancing its Decoy platform and managing the operational and financial aspects of its clinical-stage business.
Indaptus Therapeutics (Nasdaq: INDP) announces Dr. Boyan Litchev as the new Chief Medical Officer, effective January 31, 2022. Dr. Litchev brings over 20 years of experience in clinical oncology and medical leadership, having previously served at Shoreline Biosciences and Poseida Therapeutics. He will lead clinical strategies and the upcoming Phase 1 study of Decoy20, anticipated in 2022. The appointment is seen as a pivotal move towards advancing Indaptus's innovative immunotherapy platform aimed at treating various diseases through enhanced immune activation.
Indaptus Therapeutics, Inc. (Nasdaq: INDP) announces the appointment of Mark Gilbert, M.D., formerly Chief Medical Officer at Juno Therapeutics, to its Board of Directors, effective immediately. He replaces Hoonmo Lee, who has stepped down. Dr. Gilbert brings significant oncology expertise, having led pioneering CAR-T cell therapy developments. CEO Jeffrey Meckler expressed confidence that Dr. Gilbert’s experience will enhance the company’s immunotherapy pipeline. Indaptus utilizes patented technology aimed at activating both innate and adaptive immunity for cancer treatment.
Indaptus Therapeutics (Nasdaq: INDP) reported financial results for Q3 2021, highlighting a transformative quarter with the merger with Decoy Biosystems and a $30 million private placement. Research and development expenses decreased by 48% year-over-year to approximately $0.7 million, while general and administrative expenses surged by 1,260% to about $2.7 million. The company reported a loss per share of $0.81, slightly higher than $0.79 for Q3 2020. As of September 30, 2021, cash and cash equivalents stood at approximately $41.9 million, up from $1.6 million at the end of 2020.
Indaptus Therapeutics announced a significant advancement as the United States Patent and Trademark Office has allowed claims for their platform technology aimed at treating HBV and HIV infections. The patent, titled 'Methods of Treatment of Infections Using Bacteria,' grants broad protection for their innovative approach. This development validates Indaptus' strategy to activate immune responses against viral infections. The company aims to further explore partnerships for technology development, following promising pre-clinical results demonstrating enhanced therapeutic efficacy.